Abstract: The present invention relates to novel phosphorus-containing compounds with polymeric chains, and methods of making and using the same. In part, subject compositions containing phosphorus-containing compounds with polymeric chains and a therapeutic agent, and methods of making and using the same, are described. Certain of the subject compositions exhibit reverse thermal gelation.
Type:
Grant
Filed:
February 25, 2003
Date of Patent:
January 20, 2009
Assignee:
Guilford Pharmaceuticals, Inc.
Inventors:
Keith Branham, Mahesh V. Chaubal, James P. English, Donna Hall, Zhong Zhao
Abstract: The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors.
Abstract: This invention relates to new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALAdase levels are altered, effecting neuronal activity, effecting TGF-? activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers and glaucoma.
Type:
Grant
Filed:
December 19, 2002
Date of Patent:
December 12, 2006
Assignee:
Guilford Pharmaceuticals Inc.
Inventors:
Takashi Tsukamoto, Brian Grella, Pavel Majer
Abstract: The present invention relates to new thiolalkyl benzoic acids, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting TGF-? activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers, glaucoma, retinal disorders, and cancer.
Abstract: This invention provides new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, inhibiting angiogenesis, effecting a TGF-? activity or a neuronal activity, and treating a glutamate abnormality, a compulsive disorder, neuropathy, pain, a prostate disease, cancer, Huntington's disease, diabetes, a retinal disorder or glaucoma.
Abstract: A biodegradable polymer composition comprising: (a) a poly(phosphoester) biodegradable polymer and (b) at least one antineoplastic agent in an amount effective to inhibit the growth of a solid tumor, which is suitable for intratumoral administration to treat a mammal having a solid tumor.
Abstract: The present invension relates to compositions of a biocompatible polymer and a antineoplastic agent for treating central nervous system neoplasms, and methods of using and making the same. In certain embodiments, the polymer contains phosphorous linkages. In other embodiments, the antineoplastic agent is an antineoplastic taxane. In still other embodiments, the subject methods of treatment use electromagnetic radiation.
Abstract: The present invention relates to novel phosphorus-containing compounds with polymeric chains, and methods of making and using the same. In part, subject compositions containing phosphorus-containing compounds with polymeric chains and a therapeutic agent, and methods of making and using the same, are described. Certain of the subject compositions exhibit reverse thermal gelation.
Type:
Application
Filed:
February 25, 2003
Publication date:
August 18, 2005
Applicant:
Guilford Pharmaceuticals, Inc.
Inventors:
Keith Branham, Mahesh Chaubal, James English, Donna Hall, Zhong Zhao
Abstract: This invention relates to new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting TGF-? activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers and glaucoma.
Type:
Grant
Filed:
May 10, 2002
Date of Patent:
April 26, 2005
Assignee:
Guilford Pharmaceuticals Inc.
Inventors:
Takashi Tsukamoto, Pavel Majer, Bunda Hin, Weizheng Xu, Qun Liu, Doris Stoermer
Abstract: New benzenedicarboxylic acid derivative compounds; pharmaceutical compositions, diagnostic methods, and diagnostic kits that include those compounds; and methods of using those compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting TGF-? activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers, and glaucoma.
Type:
Grant
Filed:
June 21, 2002
Date of Patent:
February 8, 2005
Assignee:
Guilford Pharmaceuticals, Inc.
Inventors:
Paul F. Jackson, Takashi Tsukamoto, Barbara S. Slusher, Eric Wang
Abstract: This invention relates to new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting TGF-&bgr; activity, inhibiting angiogenesis, and treating glutamate abnormalities, diabetic neuropathy, pain, compulsive disorders, prostate diseases, cancers and glaucoma.
Type:
Grant
Filed:
May 8, 2003
Date of Patent:
November 2, 2004
Assignee:
Guilford Pharmaceuticals Inc.
Inventors:
Takashi Tsukamoto, Pavel Majer, Doris Stoermer, Barbara S. Slusher
Abstract: The present invention relates to methods for regulating the release of TGF-&bgr; from living cells in vitro or in vivo, comprising bringing the cells into contact with an effective amount of a NAALADase inhibitor. Such methods are believed to be useful for affecting neuroregeneration, cell proliferation, cell differentiation, extracellular matrix formation, myelination, inflammation, immune function, liver function, pancreatic function, angiogenesis, or wound healing; and/or for preventing or treating diabetes.
Type:
Grant
Filed:
August 1, 2002
Date of Patent:
October 19, 2004
Assignee:
Guilford Pharmaceuticals Inc.
Inventors:
Barbara S. Slusher, Xi-Chun May Lu, Krystyna Wozniak
Abstract: This invention relates to neurotrophic low molecular weight, small molecule peptidic cyclophilin inhibitor compounds having an affinity for cyclophilin-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.
Type:
Application
Filed:
April 11, 2003
Publication date:
October 14, 2004
Applicant:
Guilford Pharmaceuticals, Inc.
Inventors:
Gregory S. Hamilton, Ling Wei, Joseph P. Steiner
Abstract: The present invention relates to new thiolalkyl benzoic acids, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, effecting neuronal activity, effecting TGF-&bgr; activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers, glaucoma, retinal disorders, and cancer.
Abstract: Biodegradable, flowable or flexible polymer compositions are described comprising a polymer having the recurring monomeric units shown in formula I:
wherein:
each of R and R′ is independently straight or branched alkylene, either unsubstituted or substituted with one or more non-interfering substituents;
L is a divalent cycloaliphatic group;
R″ is selected from the group consisting of H, alkyl, alkoxy, aryl, aryloxy, heterocyclic or heterocycloxy; and
n is 5 to 1,000,
wherein said biodegradable polymer is biocompatible before and upon biodegradation. In one embodiment, one or more of R, R′ or R″ is a biologically active substance.
Amorphous compositions containing a biologically active substance, in addition to the polymer, and methods for controllably releasing biologically active substances using the compositions, are also described.
Type:
Grant
Filed:
December 4, 2001
Date of Patent:
October 5, 2004
Assignees:
Guilford Pharmaceuticals, Inc., Johns Hopkins University School of Medicine
Inventors:
Wenbin Dang, Irina Kadiyala, Zhong Zhao, James P. English, Hai-quan Mao, Kam W. Leong